Skip to main content
Publications
Mease P, Gladman D, Davenport E, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naïve subjects with active psoriatic arthritis. Poster presented at the 37th Scandinavian Congress of Rheumatology; September 5, 2018. Helsinki, Finland. [abstract] Scand J Rheumatol. 2018 Sep 5; 47(Suppl 129):34-5. Previously presented at the 2017 ACR/ARHP Annual Meeting.
Mueller N, Rojas-Rueda D, Salmon M, Martinez D, Ambros A, Brand C, de Nazelle A, Dons E, Gaupp-Berghausen M, Gerike R, Gotschi T, Iacorossi F, Panis LI, Kahlmeier S, Raser E, Nieuwenhuijsen M, PASTA consortium. Health impact assessment of cycling network expansions in European cities. Prev Med. 2018 Apr;109:62-70. doi: 10.1016/j.ypmed.2017.12.011
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept. J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.